Bristol Myers Surpasses Q2 Expectations Amid Product Growth

Bristol Myers Squibb reported better-than-expected Q2 results driven by new products like anemia treatment Reblozyl and heart drug Camzyos, with Eliquis continuing as a top-seller. The company raised its earnings forecast for the full year while addressing future revenue impacts from the Inflation Reduction Act's drug-price negotiations.

Drugmaker Bristol Myers Squibb posted impressive second-quarter results, exceeding expectations thanks to the success of new products such as the anemia treatment Reblozyl and the heart drug Camzyos, along with sustained sales from the blood thinner Eliquis.

Chief Executive Chris Boerner reported that final pricing from U.S. regulators on Eliquis will be disclosed by Sept. 1, expressing confidence in navigating the financial impacts of the Inflation Reduction Act.

The company revised its earnings forecast upward for the year, with shares rising approximately 7% to $48.41 in premarket trading. CFO David Elkins highlighted a transformation toward a new growth portfolio. Despite a slight dip in net income compared to last year, total revenue increased by 9% to $12.2 billion, outpacing analyst expectations.